Last reviewed · How we verify
NCT05586035
Analysis of Factors and Treatment Related to Chronic Cough After Pulmonary Resection
trial in Persistent Cough in 300 participants. Status unknown.
30 December 2022
Quick facts
| Lead sponsor | Guangdong Provincial People's Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 2 September 2021 |
| Primary completion | 30 December 2022 |
| Estimated completion | 30 August 2023 |
| Sites | 1 location across China |
Conditions studied
- Persistent Cough — all drugs for Persistent Cough →
- Pneumonectomy — all drugs for Pneumonectomy →
- Lung Neoplasms — all drugs for Lung Neoplasms →
Sponsor
Guangdong Provincial People's Hospital
Who can join
Adults 18 to 85, any sex, with Persistent Cough or Pneumonectomy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Surgical resection is the primary treatment for pulmonary tumors. Surgeons has been frequently concerned about effectiveness, safety, and minimal invasive techniques. However, persistent cough, one of the most common complications of lung surgery, has received insufficient attention. This study set out to investigate the risk factors and treatment related to persistent cough after pulmonary resection.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Trajectories and risk factors of persistent cough after pulmonary resection: A prospective two-center study.
Sun X, Lan Z, Li S, Huang S, et al · · 2023 · cited 14× · PMID 37920959 · DOI 10.1111/1759-7714.15147
Verify or expand the search:
- PubMed search for NCT05586035
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Guangdong Provincial People's Hospital trials
Trials by the same sponsor.
- NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
- NCT07514611 — Weight Loss Via Intelligent Guidance in Patients With Coronary Heart Disease and Obesity: a Randomized Clinical Trial · NA · recruiting
- NCT07352930 — A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Can · NA · not yet recruiting
- NCT07472478 — Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12 · Phase 2 · not yet recruiting
- NCT07483398 — RELIEF-PD: Crisugabalin for Nociplastic Pain in Parkinson's Disease · Phase 4 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05586035 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangdong Provincial People's Hospital
- Last refreshed: 19 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05586035.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing